Rhein Biotech N.V. has abandoned its blue-collar roots in enabling technology to become a more up-scale vaccine products company. Rhein (NMarkt:RBO, Maastricht, the Netherlands) had been producing and outlicensing recombinant proteins until last week, when it acquired an 80 percent stake in Green Cross Vaccine Corp., a subsidiary of Korea Green Cross, in a transaction valued at $110 million.

The deal gives RBO a product pipeline worth $60 million annually and a sales gateway to the developing